Legal & General Group PLC Magenta Therapeutics, Inc. Transaction History

Legal & General Group PLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$1.26 - $2.09 $3,010 - $4,993	-2,389 Closed	0 $0
Q2 2022 Aug 22, 2022	SELL	$0.97 - $3.08 $670 - $2,128	-691 Reduced 22.44%	2,389 $3,000
Q2 2021 Aug 12, 2021	BUY	$9.76 - $14.15 $8,032 - $11,645	823 Added 36.46%	3,080 $30,000
Q1 2021 May 17, 2021	SELL	$7.66 - $13.38 $1,470 - $2,568	-192 Reduced 7.84%	2,257 $27,000
Q3 2020 Nov 13, 2020	SELL	$6.52 - $8.94 $1,414 - $1,939	-217 Reduced 8.14%	2,449 $17,000
Q2 2020 Aug 14, 2020	SELL	$6.18 - $10.76 $3,874 - $6,746	-627 Reduced 19.04%	2,666 $20,000
Q1 2020 May 14, 2020	SELL	$6.03 - $15.24 $4,347 - $10,988	-721 Reduced 17.96%	3,293 $21,000
Q4 2019 Feb 13, 2020	BUY	$9.07 - $15.84 $6,938 - $12,117	765 Added 23.55%	4,014 $61,000
Q2 2019 Aug 14, 2019	BUY	$13.4 - $17.67 $10,854 - $14,312	810 Added 33.21%	3,249 $48,000
Q1 2019 May 15, 2019	BUY	$5.7 - $19.7 $9,969 - $34,455	1,749 Added 253.48%	2,439 $40,000
Q3 2018 Nov 20, 2018	BUY	$11.32 - $15.7 $7,810 - $10,833	690 New	690 $8,000

442K

Ticker MGTA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,890,500
Description
Magenta Therapeutics, Inc., a clinical-stage biotechnology company, develops medicines to bring the curative power of stem cell transplants to patients with blood cancers, genetic diseases, and autoimmune diseases. It develops MGTA-117, an anti-CD117 antibody that targets hematopoietic stem cells (HSCs) and genetically mutated stem cells that ca...

Get notified when there are updates to the investment portfolio of Legal & General Group PLC, based on Form 13F filings with the SEC.

Stay updated on Legal & General Group PLC with notifications on news.